ReviewClinical microbiology reviews2022
Pathogenesis of Respiratory Viral and Fungal Coinfections.
Review in Clinical microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2026Pooled it
- Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Development and internal validation of a clinical prediction model for septic shock in pediatric respiratory syncytial virus bronchiolitis based on routine blood biomarkers and concomitant fungal infection.Frontiers in cellular and infection microbiology · 2026Trial
- Invasive aspergillosis in autoimmune inflammatory rheumatic diseases: epidemiology, risk factors, diagnosis, management and challenges.Annals of medicine · 2026Review
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Spasmolytic Activity of Plant-Mediated Silver Nanoparticles from Fenugreek Seeds: Impact of Geographic Origin and Extraction Solvent.Nanomaterials (Basel, Switzerland) · 2026Article
- The Involvement of the Cryptococcal Yeast Kexin Protease in the Proteolytic Activation of the Uncleaved Influenza Virus Hemagglutinin Glycoprotein.MicrobiologyOpen · 2026Article
- Clinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancies.BMC pulmonary medicine · 2026Article
- Differential associations of pathogen-specific co-infections with disease severity in pediatric RSV hospitalizations: a 3-year multicenter analysis.Microbiology spectrum · 2026Article
- IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.Archives of microbiology · 2026Review
- Nectriatides with No Antifungal Activity Bind to Ergosterol and Potentiate the Antifungal Activity of Amphotericin B againstACS omega · 2026Article
- Respiratory Viral Co-Infections in Pediatric Patients: Clinical Impact and Implications for Healthcare Practice-A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Fungal infections of the lung during and after the COVID-19 pandemic: Retrospective observational comparison.Medicine · 2026Observational
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Biogenic Synthesis, Structural Characterization, and Biological Evaluation of Nanoparticles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic/immunotherapeutic applications against allergic aspergillosis.Annals of clinical microbiology and antimicrobials · 2026Article
- Amplified inflammatory and immune responses in viral-associated pulmonary aspergillosis.Frontiers in cellular and infection microbiology · 2026Article
- Detection ofFrontiers in cellular and infection microbiology · 2026Article
- Synthesis, Structural Characterization, and DFT Studies of Fe(III), Co(II), and Ni(II) Mixed-Ligand Complexes With Albendazole and Nifuroxazide With Molecular Docking Against Respiratory Pathogen Targets.Bioinorganic chemistry and applications · 2026Article
- Comparative clinical features and outcomes of invasive pulmonary aspergillosis following influenzaFrontiers in medicine · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Individuals suffering from severe viral respiratory tract infections have recently emerged as "at risk" groups for developing invasive fungal infections. Influenza virus is one of the most common causes of acute lower respiratory tract infections worldwide. Fungal infections complicating influenza pneumonia are associated with increased disease severity and mortality, with invasive pulmonary aspergillosis being the most common manifestation. Strikingly, similar observations have been made during the current coronavirus disease 2019 (COVID-19) pandemic. The copathogenesis of respiratory viral and fungal coinfections is complex and involves a dynamic interplay between the host immune defenses and the virulence of the microbes involved that often results in failure to return to homeostasis. In this review, we discuss the main mechanisms underlying susceptibility to invasive fungal disease following respiratory viral infections. A comprehensive understanding of these interactions will aid the development of therapeutic modalities against newly identified targets to prevent and treat these emerging coinfections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.